Tilatamig samrotecan

Specification

• Cat#: THP-3368
• Product Name: Tilatamig samrotecan
• Description: Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research.
• Species: Human
• Source: HEK293
• Purity: 98.84% by SEC-HPLC
• Storage: Keep away from direct sunlight, store at -80 centigrade.
• Appearance: Liquid
• Formulation: Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based).

Pharmaceutical Information

• Applications: ELISA; FCM; Functional assay